The use of CXCR4 as a marker to identify metastatic CSCs is in line with previous studies in pancreatic cancer, in which we showed that CD133+/CXCR4+ CSCs have exclusive tumorigenic and metastasis-initiating capacity [9]. Here, CXCR4 is linked to familial pancreatic carcinoma.